July 29, 2020
Keystone Heart Launches TriGuard 3 Cerebral Embolic Protection Device in Europe
July 29, 2020—Keystone Heart, Ltd., a Venus Medtech company, announced the completion of the first commercial case using the TriGuard 3 cerebral embolic protection (CEP) device, which is designed to minimize the risk of cerebral damage during transcatheter heart procedures. Professor Pieter Stella, MD, who is from the Medical Department of Cardiology at UMC Utrecht in Utrecht, the Netherlands, performed the transcatheter aortic valve replacement (TAVR).
“Although we have seen improvement in mortality and morbidity rates during TAVR procedures, the risk of periprocedural stroke has not changed,” commented Prof. Stella in the Keystone Heart announcement. He continued, “As a physician, I am driven to do anything possible to prevent this rare but terrible complication. I am pleased we can now routinely use the TriGuard 3 CEP device in all of our TAVR cases to protect patients from stroke, delirium, and neurocognitive decline.”
Keystone Heart began commercialization of the device in selected TAVR centers of excellence throughout Europe in July 2020.
In March 2020, Keystone Heart announced that the TriGuard 3 CEP device received CE Mark approval to cover and protect all three major cerebral aortic arch vessels during TAVR and other transcatheter heart procedures.